拓展性同情使用临床试验用药制度的相关问题研究

doi:10.19803/j.1672-8629.2021.01.09

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 47-51.
DOI: 10.19803/j.1672-8629.2021.01.09

拓展性同情使用临床试验用药制度的相关问题研究

马静, 高京宏, 刘春光^*

武警北京总队医院药剂科,北京 100027

收稿日期:2020-04-22 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*刘春光,女,硕士,主管药师,药物警戒与合理用药。E-mail:liuchunguang2019@163.com
作者简介:马静,女,博士,主任医师,临床医学与卫勤学。

Issues Related to Expanded Access to Investigational Drugs for Compassionate Use

MA Jing, GAO Jinghong, LIU Chunguang^*

Department of Pharmacy,Beijing Corps Hospital of Chinese People's Armed Police Force,Beijing 100027,China

Received:2020-04-22 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的研究国外部分国家拓展性同情使用临床试验用药制度及申请批准情况,为我国拓展性临床试验用药制度设计提供参考。方法通过查阅美国、欧盟药品监管机构发布的法规政策、技术指南、年度报告及相关文献,深入分析欧美拓展性临床试验用药的相关概念、类别、申请要求、风险获益评估等内容。结果和结论 拓展性同情使用临床试验用药是在不能通过已上市药物有效治疗严重疾病或危及生命疾病时,获得研究药物的潜在方式。美欧等地区对拓展性研究药物制定了较为完善的法规体系,因为临床试验用药并未上市,安全性和有效性证据收集不足,使用时更要保护使用者的安全,同时伦理委员会应当严格履行职责,保证患者知情同意,并对治疗方案严格审查。

关键词: 拓展性, 同情使用, 临床试验用药

Abstract: Objective To study the laws and regulations and application approval by some foreign drug regulatory agencies concerning expanded access to investigational drugs for treatment use so as to provide reference for the design of related guidelines in China.Methods By referring to the laws and regulations,technical guidelines,annual reports and relevant literature issued by drug regulatory agencies of the United States and the European Union,the relevant concepts,categories,application requirements,risk and benefit assessment of drugs used in overseas extended clinical trials were analyzed in depth.Results and Conclusion Compassionate use of clinical trial drugs is a potential way in which patients obtain research drugs when they are suffering from serious diseases or life-threatening diseases that cannot be effectively treated with marketed drugs.As research drugs are not approved into the market,evidence about their safety and efficacy is lacking.In order to ensure the safety of subjects,ethical committees need to perform their duties by conducting strict examination of treatments.

Key words: expanded access, compassionate use, clinical trials

中图分类号:

R994.11

马静, 高京宏, 刘春光. 拓展性同情使用临床试验用药制度的相关问题研究[J]. 中国药物警戒, 2021, 18(1): 47-51.

MA Jing, GAO Jinghong, LIU Chunguang. Issues Related to Expanded Access to Investigational Drugs for Compassionate Use[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 47-51.

参考文献

[1] FDA.Expanded access to investigational drugs for treatment use-policy[EB/OL].(2017-12-11)[2020-04-05].https://www.fda.gov/news-events/public-health-focus/expanded-access.
[2] FDA.Investigational New Drug (IND) application[EB/OL].(2009-11-05)[2020-01-22].https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
[3] FDA.FDA determines that vast majority of all expanded access requests may proceed[EB/OL].(2019-05-20)[2020-04-10].https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians.
[4] FDA.How to submit a request (forms)[EB/OL].(2019-09-17)[2020-03-22].https://www.fda.gov/news-events/expanded-access/expanded-access-how-submit-request-forms
[5] FDA.What are the roles and responsibilities?[EB/OL].(2019-05-09)[2020-04-10].https://www.fda.gov/news-events/expanded-access/expanded-access-information-industry#RolesResponsabilites
[6] Jonathan P,Jarow MD.Expanded access to investigational drugs:the experience of the center of drug evaluation and researchover a 10-year period[J].Ther Innov Regul Sci,2016 ,11,50(6):705-709.
[7] Gilead Sciences Initiates.Two phase 3 studies of investigational antiviral remdesivir for the treatment of COVID-19[EB/OL].(2020-02-26)[2020-04-10].https://www.gilead.com/news-and-press/press-room/press-releases/2020/2/gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19.
[8] FDA.Coronavirus (COVID-19) update:FDA continues to facilitate development of treatments[EB/OL].(2020-03-19)[2020-04-11].https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments.
[9] EMA.Guideline on compassionate use of medicinal products[EB/OL].(2007-07-19)[2020-04-10].https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-726/2004_en.pdf
[10] EMA.Conditions of use,conditions for distribution and patients targeted and conditions for safety monitoring addressed??? to member states[EB/OL].(2020-03-03)[2020-04-05].https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distri-bution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf.
[11] EMA.Questions and answers on the compassionate use of medicines in the European Union[EB/OL].(2010-01-21)[2020-03-15].https://www.ema.europa.eu/en/documents/other/questions-answers-compassionate-use-medicines-european-union_en-0.pdf
[12] EMA.How to request an opinion[EB/OL].(2010-01-21)[2020-04-15].https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf.
[13] EMA.Compassionate use programmes in Europe[EB/OL].(2017-09-20)[2020-04-10].https://www.ema.europa.eu/en/documents/presentation/presentation-compassionate-use-programmes-europe-role-ema-member-states-cbouygues-ema_en.pdf.
[14] CFDA.The general office of the General Administration of the People's Republic of China openly solicits opinions on the administrative measures for the use of drugs for clinical trials with extended sympathy (Draft for Soliciting Opinions)[EB/OL].(2017-12-15)[2020-04-13].http://www.nmpa.gov.cn/WS04/CL2095/229372.html.
[15] NMPA.Law of the People's Republic of China on Pharmaceutical Administration[EB/OL].(2019-08-27)[2020-02-13].http://www.nmpa.gov.cn/WS04/CL2076/357712.html.
[16] WHO.Ebola virus disease[EB/OL].(2019-12-01)[2020-04-18]https://www.who.int/news-room/fact-sheets/detail.
[17] NHC.Special examination and approval procedures for drugs of State Food and Drug Administration[EB/OL].(2005-11-18)[2020-02-15].http://www.nhc.gov.cn/wjw/bmgz/201105/5c7bd2102c3749af968bb2816efc770e.shtml.
[18] Sun YX,Wei FF,Feng XC,et al.Evolution and development of extended use system of clinical trial drugs in the United States[J].Chinese Journal of New Drugs(中国新药杂志),2017 (16):1880-1886.
[19] Zou LM,Qi Y,Li TL.The enlightenment of E2E guidelines on post marketing risk management of innovative drugs in China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(11):670-674.

拓展性同情使用临床试验用药制度的相关问题研究

Issues Related to Expanded Access to Investigational Drugs for Compassionate Use

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[2]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[3]	包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140.
[4]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[5]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[6]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[7]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[8]	王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194.
[9]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[10]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[11]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[12]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[13]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[14]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[15]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.